{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116082","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.281495+00:00","generated_at":"2026-06-22T01:15:49.299884+00:00","sec_items":["1.01","3.02","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hepion Pharmaceuticals Raises $20M via Private Placement of Convertible Preferred Stock","bullets":["Offering includes 1,900,000 Series F and 100,000 Series G shares at $9.50 each.","Each preferred share convertible into common at $1.00 per share (5% original issue discount).","Investors agreed to vote Series F in favor of reverse stock split; Series G votes mirror proportions.","Company filed certificates of designation and entered registration rights agreement for resale.","A.G.P./Alliance Global Partners acted as placement agent with $1M cash fee plus expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116082","json":"https://secwatch.observer/filing/0001104659-22-116082.json","markdown":"https://secwatch.observer/filing/0001104659-22-116082.md","text":"https://secwatch.observer/filing/0001104659-22-116082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465922116082/0001104659-22-116082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465922116082/tm2230043d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:15:49.299884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2d723f09459dff975c928e8ccad271b1ce22147","claim":"Hepion Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at gross proceeds of $20 million (effective 2022-11-04).","evidence_excerpt":"On November 4, 2022, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), 1,900,000 shares of the Company’s Series F Convertible Redeemable Preferred Stock, par value $0.0001 per share (the “ Series F Preferred Stock ”), and 100,000 shares of the Company’s Series G Convertible Redeemable Preferred Stock, par value $0.0001 per share (the “ Series G Preferred Stock ,” and together with the Series F Preferred Stock, the “ Preferred Stock ”), at an offering price of $9.50 per share, representing a 5% original issue discount (“ OID ”) to the stated value of $10.00 per share, for gross proceeds of $20 million in the aggregate for the Offering, before the deduction of discounts, fees and offering expenses.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465922116082/0001104659-22-116082-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"gross proceeds of $20 million"},{"label":"Effective","value":"2022-11-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}